CAMBRIDGE, Mass.--(BUSINESS WIRE)--Gloucester Pharmaceuticals today announced that its late-stage product candidate, romidepsin, was the subject of a podium presentation entitled “International Trial Confirms Romidpesin Efficacy in Refractory CTCL Patients” at the 10th International Conference on Malignant Lymphoma, held in Lugano, Switzerland. Dr. Archibald G. Prentice, Consultant Haematologist, Royal Free Hospital, London, United Kingdom and an investigator in the study presented positive data from a Phase 2b registration trial of romidepsin in patients with cutaneous T-cell lymphoma (CTCL). Romidepsin is a novel, cyclic peptide, pan-HDAC inhibitor under investigation for hematologic malignancies.
